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ABSTRACT In this report, we explore the nature of the
inductive stimuli leading to expression of the divergently reg-
ulated lymphokines interleukin 2 (IL-2) and interleukin 4
(IL-4). Elevation of cAMP levels blocks IL-2 induction while
sparing IL-4 induction. These effects are gene-specific, not
cell-specific, and can be observed in the same cells. Transient
transfection experiments using murine IL-2 regulatory se-
quences to drive expression ofa reporter gene show at least part
of the inhibition to act at the transcriptional level. The possible
biological significance of these results is indicated by the
observation that representative type 2 helper T-cell lines main-
tain significantly higher levels of cAMP per cell than a type 1
helper T-cell line. Fresh splenic CD4+ T cells, which prefer-
entially make IL-2, have particularly low levels of cAMP per
cell and a low capacity to elevatecAMP in response to forskolin.
However, their response to forskolin increases significantly
after several days of stimulation. These results suggest a
potential link between differential cAMP regulation and the
divergence of memory T cells into effector subsets.
Subsets of T cells may be defined by the way they utilize
similar stimuli to effect distinct outcomes at the transcrip-
tional level. For example, activated type 1 helper T-cell (TH1)
lines synthesize interleukin 2 (IL-2), interferon-y, and lym-
photoxin in preference to IL-4 and IL-5, which are the
products of type 2 helper T (TH2) cells (1). Both TH subsets
use CD4 as a coreceptor and recognize antigen in association
with class II major histocompatibility complex molecules. A
central question is at what level the mechanisms operate that
restrict T cells to one or another response type. The induction
of either type of gene expression response depends on two
steps: (i) the coupling of membrane receptors to intracellular
signaling pathways and (ii) the effect of the resulting signaling
mediators on transcription factors and/or on chromatin
structure and RNA stability. It is known that the frequency
of IL-2 producers in various populations and the levels of
IL-2 mRNA that they accumulate are a function of the
particular activating stimulus used (2-4). This suggests that
the ultimate response phenotype of a T cell may not be
heritably fixed but may be influenced by the type of external
stimulus it receives.
In fact, several recent reports suggest that upon repeated
exposure to antigen, CD4+ T cells in vivo do shift their
response type. In certain cases, the population appears
progressively to lose the ability to express IL-2 while en-
hancing its ability to make IL-4 (5-7). An important question
is whether such T-cell populations are developmentally pre-
programmed to differentiate from IL-2 producers to IL-4
producers or whether instead they may be altered by the
particular signaling events induced by contact with antigen.
Signaling modulation could either result in preferential acti-
vation ofa preexisting T-cell subset or result in "instructive"
modification of the gene batteries expressed by individual
responding cells. The phenomenon of THI-specific induction
of anergy (8-11) is an example of the former mechanism.
Differences between THi and TH2 clones in the coupling of
their T-cell receptors (TCR) to signaling cascades (12) rein-
force this concept of preexisting distinctions. On the other
hand, the tendency of rare clones producing both IL-2 and
IL-4 to lose expression of IL-2 preferentially, either on
extended passage (13) or on acute exposure to glucocorti-
coids (14), is an example of the latter.
This report demonstrates that the common second mes-
senger cAMP may participate in shifts to TH2-like responses
in individual cells. Established TH2 cells were found to
maintain significantly higher levels of intracellular cAMP
than THi cells. When stimuli that bypass the TCR are used
to induce both IL-2 and IL-4 in model systems, the presence
of cAMP agonists selectively blocks IL-2 induction without
affecting the induction of IL-4. The blockade of IL-2 syn-
thesis appears to be exerted at least partly by gene-specific
inhibition of transcription from the IL-2 promoter. Most
strikingly, the differential effects of cAMP on IL-2 and IL-4
expression need not simply reflect differences among cellular
subsets in susceptibility to inhibition, because they can be
observed in the same cells.
MATERIALS AND METHODS
Drugs and Reagents. Stocks of the phorbol ester phorbol
12-myristate 13-acetate (PMA) and the calcium ionophore
A23187 were made up in Me2SO and used at final concen-
trations of 10 ng/ml for PMA and 37 ng/ml for A23187. The
adenylate cyclase activator, forskolin, N6,02'-dibutyryl-
adenosine 3',5'-cyclic monophosphate (Bt2cAMP), and pros-
taglandin E1 (PGE1) were purchased from Sigma and Calbio-
chem. In all cases the final organic solvent concentration was
0.1%.
Cell Lines. The TH1 line A.E7 and the TH2 lines D10.G4.1
and CDC-25 were passaged every 7-10 days with antigen and
mitomycin C-treated feeder cells as described (15-17). The
murine thymoma EL4.E1, the human T-leukemic line Jurkat,
and the IL-3-dependent premast cell line 32Dcl5 were grown
as described (18).
Plasmids and Transfections. Plasmids containing various
amounts of the mouse IL-2 gene promoter and 5' flanking
DNA linked to the bacterial gene encoding chloramphenicol
acetyltransferase (CAT) and their transfection into cell lines
Abbreviations: CAT, chloramphenicol acetyltransferase; Bt2-
cAMP, N6,02'-dibutyryladenosine 3',5'-cyclic monophosphate;
PGE1, prostaglandin E1; TCR, T-cell receptor; TH cell, helper T cell;
PMA, phorbol 12-myristate 13-acetate; IL-1, IL-2, etc., interleukin
1, interleukin 2, etc.
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have been described in detail elsewhere (18). Transfection of
exponentially growing cells and assay of CAT activity were
as described in detail (18).
RNA Extraction and Analysis. Cytoplasmic RNA was ex-
tracted by the method of Favaloro et al. (19) and analyzed as
described (18).
cAMP Assay. Cells were resuspended at 1.5 x 106 cells per
ml in complete medium containing various stimuli. After
incubation for 15 min at 370C, the reactions were terminated
in liquid N2. Ethanol was added to 65% and the tubes were
vortex mixed until the cell pellet thawed. After clarification,
supernatants were transferred to fresh tubes, dried in a
vacuum centrifuge, and stored at -20'C until assayed. As-
says were performed on extracts from 2 x 104 to 1.5 x 105 cell
equivalents using a dual-range radioimmunoassay kit (Am-
ersham). All samples and standards were acetylated accord-
ing to the manufacturer's instructions prior to being assayed.
In the absence of competition, 60-65% of the total tracer was
precipitated and 2 fmol of competitor could readily be de-
tected.
RESULTS
TCR signaling induces IL-2 expression by the inositol phos-
pholipid pathway, using elevated intracellular Ca2+ and pro-
tein kinase C activation as dominant mediators (20). Agonists
that raise levels of intracellular cAMP can sharply antagonize
IL-2 induction (21-23). One proposed mechanism for the
inhibitory effect ofcAMP is that it acts to uncouple the TCR
from the pathway generating inositol phospholipid break-
down products (24, 25). Here we show that it can also block
IL-2 induction when saturating Ca2+ and protein kinase C
signals are provided. Fig. 1 shows that even in the presence
of optimal concentrations ofPMA and A23187, which bypass
the requirement for TCR coupling to phospholipase C, IL-2
RNA induction can be blocked in both EL4.E1 (Fig. 1A) and
Jurkat (Fig. 1B) IL-2-producer cells by agents that increase
intracellular cAMP. Forskolin (Fig. 1A, lane 7, and B, lane 5)
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and Bt2cAMP (Fig. 1A, lane 5, and B, lane 3) inhibited
responses of both cell lines in a dose-dependent manner, and
PGE1 (Fig. 1A, lanes 3 and 4), which elevates cAMP levels
more indirectly, also inhibited IL-2 induction in the EL4.E1
line. Although Jurkat and EL4.E1 are malignant cell lines,
they differ in their minimal activation requirements for IL-2
expression and clearly represent derivatives of T cells at
different stages ofdevelopment (26-28). Thus, the sensitivity
to inhibition by elevated cAMP levels seems to be charac-
teristic of the IL-2 induction pathway per se and not a
peculiarity of signal generation in a given cell type.
IL-4 expression can also be induced in response to A23187
and PMA, and two cell lines programmed to express IL-4 are
analyzed in Fig. 2. Fig. 2 Left shows the responses of
D10.G4.1 cells, a nontransformed TH2 line that requires
periodic restimulation with antigen (15), and Fig. 2 Right
shows 32Dcl5, an IL-3-dependent premast cell line (29) that
also expresses IL-4 upon stimulation (30, 31). As shown in
Fig. 2, IL-4 induction in both lines was completely insensitive
to the effects of forskolin or PGE1 at doses (10 ,uM) that
sharply inhibited accumulation of steady-state IL-2 RNA in
EL4.E1 cells. Thus, induction of lymphokine gene expres-
sion by Ca2+ and protein kinase C is not universally inhibited
by cAMP.
The cAMP insensitivity of IL-4 RNA induction was de-
monstrable not only in the D10.G4.1 and 32Dcl5 cells but also
in EL4.E1 cells themselves. These tumor cells, unlike most
long-term T-cell lines, express both IL-2 and IL-4 upon
induction (Fig. 1A, lane 2). In the presence ofcAMP agonists,
even in the absence of any detectable IL-2 RNA, the IL-4
RNA levels induced in these cells (relative to actin RNA)
were unchanged (Fig. 1A, lanes 3, 4, 5, and 7). Thus, even
within the same cells, expression of IL-2 and IL-4 RNA
appears to be regulated by distinct gene-specific pathways,
only one of which is inhibited by cAMP.
IL-2 RNA accumulation is controlled both at the level of
transcriptional induction and at the level ofRNA stabilization
(32, 33). To assess whether cAMP inhibits at the transcrip-
tional level, we utilized a series of chimeric DNA constructs
that we have derived (18) in which various extents of murine
IL-2 regulatory sequence drive expression ofa bacterial CAT
gene. In these constructs, the sequences that target natural
IL-2 RNA for degradation are deleted, and the level of CAT
enzyme produced predominantly reflects promoter activity.
Fig. 3 shows the effects of cAMP elevation on levels of
CAT activity expressed in EL4.E1 and Jurkat cells tran-
siently transfected with these constructs, with pRSV-CAT as
a control. In all cases, the cells were stimulated after trans-
fection, as described (18), and the figure shows the activity of
each construct after stimulation in the presence of the indi-
cated drugs as a fraction of its activity after stimulation in the
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FIG. 1. Effect of drugs on IL-2 mRNA induction: Increased
intracellular cAMP decreases IL-2 expression but not IL-4 expres-
sion. These gel blots of cytoplasmic RNA show the effects of
increased intracellular cAMP on lymphokine mRNA levels. For each
panel, the same filter was hybridized sequentially with probes
indicated on the left. (A) EL4.E1 cells stimulated in the presence of
various cAMP agonists. Lanes: 1, unstimulated cells; 2-8, cell
stimulated 5 hr with PMA plus A23187. Other additives were as
follows. Lanes: 2, no additives; 3, 10 ,uM PGE1; 4, 1 ,uM PGE1; 5,
1 mM Bt2cAMP; 6, 0.1 mM Bt2cAMP; 7, 10 ,M forskolin; and 8, 1
,M forskolin. (B) Jurkat cells. Lanes: 1 and 2, as in A; 3, 1 mM
Bt2cAMP; 4, 0.1 mM Bt2cAMP; 5, 10 uM forskolin; 6, 1 ,uM
forskolin.
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FIG. 2. Insensitivity of IL-4 induction to cAMP regardless of cell
type: 32Dc15 (lanes 1-6) and D1O.G4.1 (lanes 7-12). Cytoplasmic
RNA was separated electrophoretically and hybridized with the
indicated probes as in Fig. 1. Cells were left unstimulated (lanes 1 and
7) or were stimulated for 5 hr with PMA plus A23187 alone (lanes 2
and 8) or in the presence of 10 ,uM (lanes 3 and 9) or 1 ,M (lanes 4
and 10) forskolin and 10 ,uM (lanes 5 and 11) or 1 ;LM (lanes 6 and 12)
PGE1.
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FIG. 3. Increased intracellular cAMP depresses expression of
CAT from the IL-2 promoter in a promoter-specific way. (A) EL4.E1
cells transfected with the indicated plasmids were stimulated with
PMA plus A23187 for 18 hr in the presence and absence of 10 ,uM
forskolin. For each plasmid results were calculated as [(CAT activity
with drug)/(CAT activity without drug)] x 100. Results are given as
mean ± range or SEM of two or three experiments. Similar results
were obtained with a treatment of 1 mM PGE1 (data not shown). (B)
Effect of 1 mM Bt2cAMP on IL-2-CAT expression in Jurkat cells
relative to drug-free controls. Results shown are from a single
experiment. RSV, Rous sarcoma virus.
absence of the drug. Expression of all the pIL-2-CAT plas-
mids was suppressed by 30-80% in the presence of cAMP
agonists, relative to their drug-free controls. Similar results in
EL4.E1 cells were achieved with 1 /iM PGE1 (data not
shown). At the same time, however, pRSV-CAT expression,
which is also up-regulated by PMA and A23187, was mini-
mally inhibited in Jurkat cells and actually increased an
additional 4-fold in EL4.E1 cells under these conditions.
Thus, the suppressive effects of cAMP on the pIL-2-CAT
plasmids are not attributable to a generalized down-
regulation of transcription, translation, or activation path-
ways. Instead, the same intracellular signal in the same T-cell
population gives different effects on transcriptional induc-
tion, depending on the inducible gene being studied. Thus, at
least one component of the cAMP effect on IL-2 induction
affects transcriptional activity of the IL-2 gene in a promoter-
specific manner.
Although cAMP agonists only partially inhibited IL-2-
CAT expression, the inhibition was most pronounced at early
times after induction. The greater inhibitory effect seen at 18
hr in the experiment shown with Jurkat (>75% inhibition) as
compared to EL4.E1 (50%o) reflected the slower kinetics of
IL-2-CAT induction in Jurkat cells (unpublished observa-
tions). When extracts of stimulated EL4.E1 cells were as-
sayed at 5 hr rather than 18 hr, 10 AtM forskolin also caused
more severe inhibition (.70%; also, P. M. White and
E.V.R., unpublished results). The initial kinetics of CAT
product accumulation are more likely to be dominated by
relative transcription rates per se and less by effects on
transcript stability and translational efficiency than later
plateau values. The greater inhibition at early times thus
supports the interpretation that cAMP in fact inhibits tran-
scription from the IL-2 promoter.
Other mechanisms might contribute to the effect of cAMP
on IL-2 accumulation. The degree of inhibition of IL-2-CAT
expression by cAMP was consistently less severe than the
inhibition of endogenous IL-2 RNA accumulation. However,
as the kinetics of IL-2-CAT induction in EL4.E1 cells are
slower than those of IL-2 mRNA induction, single time-point
measurements of their accumulated levels may not be di-
rectly comparable. Our results could suggest either that the
effect of cAMP is transient or that it exerts some effects on
IL-2 RNA at the post-transcriptional level.
To assess the biological significance of increased intracel-
lular cAMP, we examined several T-cell populations that
selectively produce IL-2 or IL-4. In addition to the TH2 lines
D10.G4.1 and CDC-25, we also examined a cloned THi line,
A.E7 (16). When assayed 7 days after stimulation with
antigen, D10 cells contained 3 times more cAMP on a per-cell
basis than A.E7 cells (Table 1). This difference in baseline
cAMP levels was also seen 4 days after antigenic stimulation
when both lines were actively proliferating. Another TH2
line, CDC-25, contained even higher levels of cAMP. Thus,
A.E7 cells maintain a low level of cAMP that is independent
of their proliferative status.
The level of cAMP in these lines did not change signifi-
cantly after stimulation with PMA plus A23187 or anti-CD3
plus IL-1. It therefore appears that the stable response
phenotypes of these cloned lines are correlated with stably
maintained differences between their levels of cAMP. Be-
cause cell lines may not be representative of normal cells, we
also examined cAMP levels in CD4+ splenic T cells. This
laboratory has shown (3) that almost 100% of these cells
synthesize IL-2 mRNA in response to PMA plus A23187.
These cells have also been shown to secrete little, if any, IL-4
(5, 34). As shown in Table 1, freshly isolated CD4+ T cells
have resting levels of cAMP that are comparable to or slightly
lower than those of A.E7 cells. Intriguingly, they even
manifest a poor response to forskolin at this time. After
several days of culture in the presence of concanavalin A and
IL-4, many CD4+ T cells acquire the ability to secrete IL-4
(35). These cells still maintained a relatively low level of
cAMP that did not change when stimulated with PMA plus
A23187 or anti-CD3 plus IL-1. However, they had acquired
the ability to respond well to forskolin, a property that was
evident by day 2 of culture. It is therefore possible that these
cells could increase their intracellular pools of cAMP signif-
icantly more than fresh CD4+ cells if they were triggered
appropriately (see below). Thus, while the details of any such
developmental changes remain to be explored, the results
presented in Table 1 support a correlation between high
cAMP levels and preferential production of IL-4 relative to
IL-2.
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Table 1. cAMP levels in IL-2 producer and nonproducer
T-cell populations
cAMP, fmol per
Time of Stimulation 106 cells
Cell assay conditions Exp. 1 Exp. 2
D10.G4.1 Day 4 - 700
Day 7 - 507 547
Day 7 PMA/A23187 700 547
Day 7 Forskolin 1633 1800
Day 7 CD3/IL-1 653 360
CDC-25 Days 3-5 - 3500 4800
A.E7 Day 4 - 160
Day 7 - 160 190
Day 7 PMA/A23187 200 147
Day 7 Forskolin 2560 733
Day 7 CD3/IL-1 230 147
CD4' spleen* Day 0 - 113 87
Day 0 PMA/A23187 93
Day 0 Forskolin 600 767
Day 0 CD3/1L-1 93
Day 2 - 180
Day 2 Forskolin 4100
Day 4 - 160
Day 4 PMA/A23187 160
Day 4 Forskolin 4267
Day 4 CD3/IL-1 173
D10.G4.1, CDC-25, and A.E7 cells were stimulated with antigen-
and mitomycin C-treated spleen cells on day 0. Four and 7 days later
cells were harvested and assayed for cAMP after no treatment (-) or
after 15 min at 370C with the indicated stimuli. In experiment 1,
healthy CDC-25 cells were assayed 24 hr after thawing. Spleen cells
were depleted of B cells by "panning" on goat anti-mouse immu-
noglobulin-coated plates and CD8' T cells were eliminated by two
rounds of complement-mediated lysis (day 0). Day 2 spleen cells
were grown in the presence of concanavalin A (3 ,ug/ml) and PMA
(3 ng/ml). Day 4 cells received concanavalin A (2 ,ug/ml) on day 0.
On day 1 the cells received 5% (vol/vol) EL4-conditioned medium
and recombinant IL-4 (20 units/ml). Cells were stimulated with PMA
and A23187 at concentrations of 10 ng/ml and 37 ng/ml, respectively.
Anti-CD3 (E) antibody 145-2C11 was used to coat polystyrene tubes
and recombinant human IL-la was used at a final concentration of
100 units/ml. Forskolin was used at 10 ,uM.
*Day 0 cells were >95% CD4+ T cells in experiment 1 and were
contaminated with l9o B cells in experiment 2. Day 4 cells were
from a different starting population, and at the time of harvest were
>75% T cells of which >99o were CD4+.
DISCUSSION
We have shown that, in a variety of clonal cell lines,
treatments that elevate intracellular cAMP levels can abort
IL-2 RNA induction while leaving IL-4 induction, by the
same pharmacological stimuli, unaffected. A particularly
dramatic example is provided by the EL4.E1 line, where
induction of the two lymphokines can be differentially af-
fected within the same cells. Under the conditions used here,
80-100% of these EL4.E1 cells accumulate IL-2 RNA in the
absence ofcAMP (unpublished results). Thus, it is likely that
the same cells that appear cAMP-resistant for IL-4 RNA
induction are also cAMP-sensitive for IL-2 RNA induction.
Although both lymphokine genes can be induced by Ca2+
ionophores and phorbol esters as well as TCR-mediated
signaling, their induction pathways are in fact distinct.
The effect ofcAMP on IL-2 accumulation at least includes
a component of transcriptional inhibition. In spite of the
various degrees of inhibition observed under different con-
ditions, all of the nested series of 5' IL-2-CAT constructs
tested here were inhibited by cAMP to the same extent within
experimental error. Thus, neither the weak negative regula-
tory sites nor the positive regulatory regions that we have
identified (18) upstream of position -321 are likely to be
specific targets of the cAMP pathway blocking IL-2 induc-
tion. This conclusion is in agreement with the absence of
identifiable "cAMP response elements" in the entire 2800
base pairs of IL-2 5' flanking sequence (18). However, more
recent data suggest that cAMP inhibition involves a complex
of positive and negative factors acting at distinct sites (ref. 36;
P. M. White and E.V.R., unpublished results).
The differential inhibition of IL-2 by cAMP may be more
than a pharmacological curiosity in vitro. Accumulating
evidence suggests that THi and TH2 type memory cells may
be divergent products of a single CD4' lineage, with at least
one intermediate cell type capable of expressing both IL-2
and IL-4. With elevated cAMP levels, such cells could
behave indistinguishably from TH2 cells. It is, therefore,
provocative that we find that D1O.G4.1 and CDC-25 cells
sustain levels of cAMP throughout their stimulation cycle
that are consistently higher than those ofA.E7 cells. The high
levels of cAMP found in the TH2 cells also distinguish them
sharply from freshly isolated thymocytes (data not shown) or
splenocytes, all of which make IL-2 much more readily than
IL-4 in our hands (T.J.N., Dan Chen, and E.V.R., unpub-
lished results; ref. 3).
The levels of cAMP in D1O.G4.1 cells are unlikely to be
sufficiently high to explain the complete block to IL-2 induc-
tion in these cells; the similar concentrations induced by
forskolin treatment in fresh spleen cells only reduce IL-2
secretion by 3- to 5-fold (Patricia M. White and E.V.R.,
unpublished results). Nevertheless, cAMP at 500-700 fmol
per 106 cells may participate in "handicapping" the induction
pathway for IL-2. The cAMP concentration we find in
CDC-25 cells is more likely to be prohibitive in itself. It is also
intriguing to speculate that these elevated cAMP levels are a
relic of a more acute mechanism that originally drove the
transition of some bifunctional precursor cells into the TH2
functional type. Further work will be needed to test this
possibility, but our results with splenic CD4' cells may
provide a starting point. Fresh resting splenic CD4' cells
displayed only a modest ability to elevate cAMP in response
to forskolin, suggesting that their adenylate cyclase activity
is relatively low and/or their phosphodiesterase activity is
high. Two to 4 days after activation, the main difference
observed was a sharp increase in the magnitude of their
forskolin response. Thus, not their level of cAMP per se but
their capacity to elevate cAMP in response to potential
stimuli was significantly enhanced. Such preactivated cells
could be much more susceptible than fresh resting CD4+ cells
to environmental stimuli that, unlike the artificial ones tested
here, do activate adenylate cyclase. Thus, although repeated
stimulation need not shut off IL-2 inducibility directly,
through use of cAMP, repeated stimulation could make loss
of IL-2 inducibility much more probable.
A report by Groux et al. (37) reinforces the possibility that
elevation of cAMP may be especially implicated in signaling
in memory TH2 cells. In humans, CD29 expression has long
been used as a specific marker of memory T cells, in
particular those that provide help most efficiently for B cells
(38-41). B-cell help commonly reflects the production of IL-4
and IL-5 more than that of IL-2 (42). Furthermore, CD29, or
a close relative, appears to act as a Peyer's patch homing
receptor (43) [i.e., a component of the mechanism that
selectively concentrates those helper cells in vivo whose
effects are most TH2-like]. It is thus particularly interesting
that CD29 molecules can directly transduce signals leading to
sustained cAMP accumulation, with concomitant decreases
in the inducibility of IL-2 (37). The memory-cell marker may
thus participate in directing the memory-cell-specific re-
sponse.
Proc. Nati. Acad. Sci. USA 87 (1990)
Proc. Nati. Acad. Sci. USA 87 (1990) 9357
Of course, the ability of cAMP agonists to mimic the
"6THO" to "TH2" transition in one step does not prove that
cAMP is the primary regulator of T-cell functional type. It
does, however, suggest a general theme for the programming
of T-cell effector subclasses. Use of common second mes-
sengers like cAMP in a critical balance with other activation
signals to dictate not only the magnitude but also the nature
of a response provides a highly plastic, reversible way of
controlling functional identity. It may be that such mecha-
nisms play a dominant role in the differentiation of the highly
diverse family of hematopoietic cell types.
Note. After this manuscript was submitted, Mufioz et al. (44) reported
results complementary to ours and confirmed that forskolin and
cholera toxin block PMA plus ionomycin induction of IL-2 in a TH1
line.
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